Literature DB >> 2527251

Role of antigen selectivity in autoimmune responses to the Ku (p70/p80) antigen.

W H Reeves1, Z M Sthoeger, R G Lahita.   

Abstract

Levels of anti-Ku (p70/p80) antibodies were measured longitudinally in sera from four individuals with systemic lupus erythematosus or related disorders. Antibodies to the native Ku antigen (p70/p80 complex) varied over a range of up to 577-fold. Large fluctuations were also observed in the levels of autoantibodies to several distinct epitopes of the Ku (p70/p80) antigen. Levels of these individual autoantibody populations generally paralleled one another, suggesting that they are coordinately regulated. A similar pattern of anti-DNA antibody fluctuation was seen in some sera. To examine the possibility that these autoantibodies were generated by polyclonal B cell activation, the levels of anti-Ku (p70/p80) and anti-DNA antibodies were compared to the levels of antibodies to Escherichia coli proteins, tetanus toxoid, and bovine insulin, transferrin, cytochrome c, serum albumin, and thyroglobulin. In sera from the same individual, anti-Ku (p70/p80) antibodies were sometimes produced in the complete absence of polyclonal activation, and at other times were accompanied by increased polyclonal activation. Anti-DNA antibody levels more closely paralleled the level of polyclonal activation than did the anti-Ku (p70/p80) levels. These studies suggest that anti-Ku (p70/p80) antibodies are generated by an antigen-selective mechanism, but that polyclonal activation frequently, although not invariably, accompanies autoantibody production. This observation is consistent with the possibility that polyclonal activation might be secondary to autoantibody production.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2527251      PMCID: PMC548916          DOI: 10.1172/JCI114199

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  Molecular cloning of cDNA encoding the p70 (Ku) lupus autoantigen.

Authors:  W H Reeves; Z M Sthoeger
Journal:  J Biol Chem       Date:  1989-03-25       Impact factor: 5.157

2.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

3.  Deoxyribonucleic acid antibody: a method to detect its primary interaction with deoxyribonucleic acid.

Authors:  R T Wold; F E Young; E M Tan; R S Farr
Journal:  Science       Date:  1968-08-23       Impact factor: 47.728

4.  Quantitation of precipitating antibodies to certain soluble nuclear antigens in SLE.

Authors:  P J Maddison; M Reichlin
Journal:  Arthritis Rheum       Date:  1977-04

Review 5.  Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine.

Authors:  E M Tan
Journal:  Adv Immunol       Date:  1982       Impact factor: 3.543

6.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

7.  Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap.

Authors:  T Mimori; M Akizuki; H Yamagata; S Inada; S Yoshida; M Homma
Journal:  J Clin Invest       Date:  1981-09       Impact factor: 14.808

8.  Independent expression of autoantibodies in systemic lupus erythematosus.

Authors:  G A McCarty; J R Rice; M L Bembe; D S Pisetsky
Journal:  J Rheumatol       Date:  1982 Sep-Oct       Impact factor: 4.666

9.  Enzyme and radioimmunoassays for specific murine IgE and IgG with different solid-phase immunosorbents.

Authors:  A Giallongo; L Kochoumian; T P King
Journal:  J Immunol Methods       Date:  1982-08-13       Impact factor: 2.303

10.  Use of Epstein-Barr virus-transformed B cell lines for the generation of immunoglobulin-producing human B cell hybridomas.

Authors:  N Chiorazzi; R L Wasserman; H G Kunkel
Journal:  J Exp Med       Date:  1982-09-01       Impact factor: 14.307

View more
  6 in total

Review 1.  B-cell epitopes of autoantigenic DNA-binding proteins.

Authors:  C H Chou; M Satoh; J Wang; W H Reeves
Journal:  Mol Biol Rep       Date:  1992-06       Impact factor: 2.316

2.  Murine monoclonal antibodies specific for conserved and non-conserved antigenic determinants of the human and murine Ku autoantigens.

Authors:  J Wang; C H Chou; J Blankson; M Satoh; M W Knuth; R A Eisenberg; D S Pisetsky; W H Reeves
Journal:  Mol Biol Rep       Date:  1993-06       Impact factor: 2.316

3.  p70 lupus autoantigen binds the enhancer of the T-cell receptor beta-chain gene.

Authors:  H Messier; T Fuller; S Mangal; H Brickner; S Igarashi; J Gaikwad; R Fotedar; A Fotedar
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

4.  International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis.

Authors:  Katja Lakota; Gerhard G Thallinger; Snezna Sodin-Semrl; Blaz Rozman; Ales Ambrozic; Matija Tomsic; Sonja Praprotnik; Sasa Cucnik; Katjusa Mrak-Poljsak; Angela Ceribelli; Ilaria Cavazzana; Franco Franceschini; Jiri Vencovsky; Laszlo Czirják; Cecilia Varjú; Gunther Steiner; Martin Aringer; Bojana Stamenkovic; Oliver Distler; Marco Matucci-Cerinic; Tanja Kveder
Journal:  Arthritis Res Ther       Date:  2012-01-06       Impact factor: 5.156

Review 5.  Fumarase: From the TCA Cycle to DNA Damage Response and Tumor Suppression.

Authors:  Michael Leshets; Yardena B H Silas; Norbert Lehming; Ophry Pines
Journal:  Front Mol Biosci       Date:  2018-07-25

6.  BANK1 and BLK act through phospholipase C gamma 2 in B-cell signaling.

Authors:  Manuel Bernal-Quirós; Ying-Yu Wu; Marta E Alarcón-Riquelme; Casimiro Castillejo-López
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.